Media

Lonza Prices CHF 235 Million Dual Tranche Straight Bonds

FOR IMMEDIATE RELEASE

Contact:

Dirk Oehlers

Head Investor Relations
+41 61 316 8540
dirk.oehlers@lonza.com


Dominik Werner
Head Corporate Communications
+41 61 316 8798
dominik.werner@lonza.com

Constance Ward
Head External Communications
+41 61 316 8840
constance.ward@lonza.com

BASEL, SWITZERLAND– Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), today announced the pricing of its dual tranche CHF 235 million straight bonds. The bonds have a maturity of 4 and 7 years respectively with coupons of 0.200% and 0.700%.

The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the SIX Swiss Exchange. The proceeds of the bonds will be used for the refinancing of the Capsugel acquisition.

Key Data

Issue Size 4-Year Bond:          CHF 125 million

Expected Payment Date:         12 July 2017

Maturity:                                     12 July 2021 (4 years)

Issue Price:                               100.179 percent

Redemption Price:                   100 percent

Coupon:                                      0.200 percent p.a.

Joint Lead Managers:               BNP Paribas (Suisse) AG, Credit Suisse AG,
UBS AG and Zürcher
Kantonalbank

Issue Size 7-Year Bond:          CHF 110 million

Expected Payment Date:         12 July 2017

Maturity:                                     12 July 2024 (7 years)

Issue Price:                               100.222 percent

Redemption Price:                   100 percent

Coupon:                                      0.700 percent p.a.

Joint Lead Managers:               BNP Paribas (Suisse) AG, Credit Suisse AG,
UBS AG and Zürcher
Kantonalbank


About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Return Home